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Background: Redirection of T lymphocytes against tumor antigens can induce dramatic regression of advanced stage
malignancy. The use of bispecific antibodies (BsAbs) that bind both the T-cell receptor (TCR) and a target antigen is
one promising approach to T-cell redirection. However, BsAbs indiscriminately bind all CD3+ T-cells and trigger
TCR activation in the absence of parallel costimulatory signals required to overcome T-cell unresponsiveness or anergy.
Methods: To address these limitations, a combination platform was designed wherein a unique BsAb referred to as
frBsAb exclusively engages T-cells engineered to express a novel chimeric receptor comprised of extracellular
folate receptor fused to intracellular TCR and CD28 costimulatory signaling domains in tandem; a BsAb-binding
immune receptor (BsAb-IR). As a surrogate TCR, the BsAb-IR allows for concomitant TCR and costimulatory signaling
exclusively in transduced T-cells upon engagement with specific frBsAbs, and can therefore redirect T-cells on command
to desired antigen. Human primary T-cells were transduced with lentiviral vector and expanded for 14–18 days. BsAb-IRs
were harvested and armed with frBsAbs to test for redirected cytotoxicity against CD20 positive cancer cell lines.
Results: Using frBsAbs specific for CD20 or HER2, the lytic activity of primary human T-cells expressing the BsAb-IR was
specifically redirected against CD20+ leukemic cells or HER2+ epithelial cancer cells, respectively, while non-engineered
T-cells were not activated. Notably, elimination of the CD28 costimulatory domain from the BsAb-IR construct significantly
reduced frBsAb-redirected antitumor responses, confirming that frBsAbs are capable of delivering simultaneous TCR
activation and costimulatory signals to BsAb-IR T-cells.
Conclusion: In summary, our results establish the proof of concept that the combination of BsAbs with
optimized gene-engineered T-cells provides the opportunity to specify and augment tumor antigen-specific T-cell
activation and may improve upon the early success of conventional BsAbs in cancer immunotherapy.
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Antigen-specific monoclonal antibodies (mAbs) are estab-
lished as immunotherapeutic agents for the treatment of
human malignancies such as non-Hodgkin lymphoma
(NHL), CD30-positive lymphoma [1,2], EGFR-expressing
advanced bowel cancer, metastatic colorectal carcinoma
[3-6]. However, the therapeutic efficacy of tumor antigen-
specific mAbs can be limited in cancer therapy due to
their poor recruitment of the adaptive immune response.
To address this, other strategies were employed, including
the development of bispecific antibodies (BsAbs) [7,8].
While a mAb recognizes a single antigen target and
closely resembles a naturally-occurring antibody, a BsAb
is a synthetic construct that aligns two antigen-specific
binding potentials within one molecule enabling the link-
ing of two distinct antigens [9]. BsAbs generally couple
T-cells, through a T-cell receptor (TCR)-CD3-specific
antibody, with target cells, via an antigen-specific anti-
body. As a result, cancer cells are killed when cytotoxic
T lymphocytes are engaged to antigen-expressing tumor
cells and simultaneously activated by the arm of the BsAb
that triggers TCR activation [10,11]. Most BsAbs rely on
re-direction of cytotoxic T-cells, the most powerful ef-
fector cells of the immune system [12], where the BsAb
indiscriminately engages all available TCR CD3 molecules
and overrides the natural antigen-specificity of T-cells.
While TCR activation alone by BsAbs can activate
T-cells, stimulation of T-cell activity is a complex, so-
phisticated process regulated by an assortment of mole-
cules that provide activating, inhibiting or costimulatory
signals to T-cells. One fundamental tenet of T-cell immu-
nobiology is that sustained stimulation via TCR CD3
(signal 1) without parallel costimulatory signals, such
as those provided by CD28 receptor, results in im-
paired T-cell activation with induction of anergy or
apoptosis [13]. Accordingly, CD3-based immunother-
apy with BsAbs may be improved by provision of
accessory costimulation ex vivo or in vivo to elicit potent,
long-lasting antitumoral effects. This can be achieved by
ex vivo activation of cytotoxic T-cells [14,15], or by sys-
temic administration of IL-2 cytokine [16,17]. Alternatively,
technological advances have led to the development of new
BsAb strategies which simultaneously trigger the activation
of costimulatory receptors (e.g., CD28, 4-1BB, OX40) in
conjugation with conventional BsAbs treatment [18,19].
Parallel costimulatory signaling can also be provided by
combining BsAbs with an agonistic anti-CD28 mAb to me-
diate a synergistic effect in eliciting an antitumor response
in vitro [20,21]. Similarly, 4-1BB-mediated costimulation at
the tumor site can enhance T-cell activation mediated by a
BsAb [22,23], as evidenced by increased T-cell cytokine
release, activation marker expression, and proliferation.
While it is increasingly evident that BsAb approaches that
incorporate parallel costimulation are more effective thanconventional BsAb, the undefined optimal stoichiometry
of multiple receptor engagement and the indiscriminant
nature of T-cell engagement represent still represent chal-
lenges to the field.
Here, we sought to establish a proof of concept that
the needs for costimulation, fixed stoichiometry and
T-cell specification of conventional BsAbs can be re-
solved through the use of advanced T-cell engineering
strategies. We and others have previously shown that
human T-cells engineered to express a chimeric anti-
gen receptor (CAR) containing an extracellular tumor
antigen-specific antibody fused to intracellular TCR CD3
and costimulatory domains in tandem receive dual TCR
(signal 1) and costimulatory (signal 2) upon antigen en-
counter that reinforce T-cell activation, proliferation and
cancer killing [24-26]. Based upon this principle, we have
designed a novel platform that combines the application
of a BsAb with T-cells that are genetically engineered
to express a unique BsAb-binding immune receptor
(BsAb-IR). Here, the BsAb-IR is comprised of a portion
of an extracellular folate receptor (FR; 231aa) fused to
intracellular TCR and CD28 costimulatory signaling do-
mains in tandem, and can be bound and activated by an
anti-FR antibody arm of a unique BsAb that bridges FR and
tumor antigen (frBsAb). Using frBsAbs of diverse antigen
specificities, we show that tumor antigen-specific frBsAbs
specifically bind target antigen on human tumor cells and,
upon co-engagement of the BsAb-IR on engineered T-cells,
delivers simultaneous TCR CD3 activation and CD28 costi-
mulation signals in a target dependent manner, resulting in
the selective augmentation of activation, proliferation and
antitumor activity of BsAb-IR T-cell subset.
Materials and methods
BsAb-binding immune receptor (BsAb-IR) construction
Folate Receptor alpha (FR) DNA sequence was amplified
using primers: 5′-AAAAGCCTAGGATCC-3′ and 5′-A
ACCGCGCTAGCAAA-3′. After amplification and the
insertion of 3′-Bam-H1 and 5′-Nhe-1 restriction sites,
PCR product was digested with Bam-HI and NheI enzymes
and ligated into pELNS, a third generation self-inactivating
lentiviral expression vector, containing human CD3z or
CD28-CD3z signaling endodomains, under an EF-1α pro-
moter. The resulting constructs were designated pELNS
FBIR-zeta and pELNS FBIR-28z, respectively.
Recombinant lentivirus production
High-titer replication-defective lentiviral vectors were pro-
duced and concentrated as previously described [27,28].
Briefly, 293 T human embryonic kidney cells were trans-
fected with pVSV-G (VSV glycoprotein expression plas-
mid), pRSV.REV (Rev expression plasmid), pMDLg/p.RRE
(Gag/Pol expression plasmid), and pELNS transfer plas-
mid using Lipofectamine 2000 (Invitrogen). The viral
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Viral particles were concentrated and resuspended in
0.5 ml by ultracentrifugation for 2.5 h at 25,000 rpm with
a Beckman SW28 rotor (Beckman Coulter, Fullerton, CA).
T-cells
Primary human CD4+ and CD8+ T-cells were isolated
from healthy volunteer donors following leukapheresis
by negative selection, and purchased from the Human
Immunology Core at University of Pennsylvania. All speci-
mens were collected under a University Institutional
Review Board-approved protocol, and written informed
consent was obtained from each donor. T-cells were
cultured in complete media (RPMI 1640 supplemented
with 10% heat inactivated fetal bovine serum (FBS),
100 U/ml penicillin, 100 ug/ml streptomycin sulfate,
10-mM HEPES), and stimulated with anti-CD3 and
anti-CD28 mAbs coated beads (Invitrogen) as described.
24 hr after activation, T-cells were transduced with lenti-
viral vectors at MOI of ~5-10. Human recombinant
interleukin-2 (IL-2; Novartis) was added every other
day to 50 IU/ml final concentration and a 0.5-1×106
cells/ml cell density was maintained. Rested engineered
T-cells were adjusted for identical transgene expres-
sion prior to functional assays. For the investigation
into the effects of dose of folic acid, T-cells were cul-
tured in RPMI 1640, 10% heat inactivated fetal bovine
serum (FBS), 100 U/ml penicillin, 100 ug/ml streptomycin
sulfate, 10-mM HEPES) supplemented with 40 mg/l folic
acid (Sigma-Aldrich).
Cell lines
Lentivirus packaging was performed in the immortal-
ized normal fetal renal 293 T cell line purchased from
ATCC. Human cell lines used in immune based assays
include CD20 positive cell lines Ramos and Daudi.
293 T cells and tumor cell lines were maintained in
RPMI-1640 (Invitrogen) supplemented with 10% (v/v)
heat-inactivated FBS, 2 mM L-glutamine, and 100 μg/mL
penicillin and 100U/mL streptomycin. All cell lines were
purchased from ATCC.
BsAb heteroconjugation
The BsAbs were engineered by heteroconjugating cross-
linked mAbs. Anti-CD3 (Orthoclone OKT-3, Orthobiotech,
Bridgewater, NJ, USA) or anti-FR alpha (MOV18 Ab, Enzo
Life Sciences) was cross-linked with 2-iminothiolane HCl
(Pierce, Rockford, IL, USA) or trastuzumab (Herceptin,
Genentech, San Francisco, CA) and rituximab (Rituxan;
Genentech, South San Francisco, CA, USA) was cross-
linked with sulphosuccinimidyl 4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (Pierce), purified on PD-10
columns (BioRad Laboratories, Hercules, CA, USA),and heteroconjugated overnight at 4°C and analyzed by
non-reducing SDS-PAGE as described earlier [29,30].
Flow cytometric analysis
The following mAbs were used for phenotypic analysis:
APC-Cy7 Mouse Anti-Human CD3; FITC-anti-human
CD4; APC-anti-human CD8; (BD Biosciences). Tumor
cell surface expression of HER2 was detected by trastu-
zumab antibody (Herceptin, Genentech, San Francisco,
CA), CD20 by biotinylated rituximab (Rituxan; Genentech,
South San Francisco, CA, USA) followed by incubation with
Strepavidin-APC. BsAb-IR expression was detected by
Mov18/ZEL antibody (Enzo Life Sciences) followed by anti-
mouse FITC or APC conjugated antibody (LifeBioscience).
The isotype controls mIgG-APC-Cy7, mIgG-FIT, mIgG-
APC, mIgG-PerCpCy5, mIgG-Pacific-Blue-A, and mIgG-
PE-Cy7 were from eBiosciences and anti-mouse-AF488
from Invitrogen. Flow cytometric data were analyzed
by FlowJo software. For intracellular staining, cells
were permeablized using the FoxP3 staining buffer set
(eBioscience), according to manufacturer’s instructions
and labeled with: anti-human IFNg-PacificBlue, anti-human
IFNg-PerCpCy5, anti-human TNFa-APC, anti-human IL2-
PeCy7 (BD Biosciences).
Cytokine release assays and intracellular cytokine staining
Cytokine release assays were performed by co-culture of
1×105 BsAb-IR T-cells with immobilized MOV18Ab (anti-
FR alpha) or IgG1 (100 ng/ml). For co-culture experi-
ments against tumor cells, 1×105 target cells were labeled
with frBsAbs at 100 ng/106 cells for 30 min at 4°C, per
well in triplicate in 96-well round bottom plates, T-cells
were added into the culture at the E:T 1:1 ratio, in a final
volume of 200ul of T-cell media. After 16 h, co-culture
supernatants were assayed for presence of IFNg using
an ELISA Kit, according to manufacturer’s instructions
(Biolegend). Values represent the mean of triplicate
wells. IFNg, IL2, IL-4, TNFa and MIP-1a cytokines were
measured by flow cytometry using Cytokine Bead Array,
according to manufacturer’s instructions (BD Biosciences).
For cytokine staining cells were stimulated in 37°C for
around 6 h in the presence of Golgistop (BD Biosciences)
and monensin (Sigma). Cells were washed, Fc blocked,
and stained with MOV18AB-FITC then permeablized and
stained with anti-IFNg, TNFa, or isotype controls in per-
meablization buffer for 30 min.
Cytotoxicity assays
51Cr release assays were performed as described [31].
Target cells were labeled with frBsAbs at 100 ng per 106
cells for 30 min at 37°C in PBS/2%FBS. Next, antibody
labeled cells were labeled with 100uCi 100 mCi 51Cr at
37°C for 1.5 hours. Target cells were washed three times
in PBS, resuspended in CM at 105 viable cells/mL and
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cells were washed twice in CM and added to wells at the
given ratios. Plates were quickly centrifuged to settle cells,
and incubated at 37°C in a 5% CO2 incubator for 4 hours.
The supernatants were harvested, transferred to a lumar-
plate (Packard) and counted using a 1450 Microbeta Liquid
Scintillation Counter (Perkin-Elmer). Spontaneous 51Cr re-
lease was evaluated in target cells incubated with medium
alone. Maximal 51Cr release was measured in target cells
incubated with SDS at a final concentration of 2% (v/v).
Percent specific lysis was calculated as (experimental -
spontaneous lysis/maximal - spontaneous lysis) times 100.
Statistical analysis
Student’s t test was used to evaluate differences in T-cells
specific cytolysis. GraphPad Prism 4.0 (GraphPad Soft-
ware) was used for the statistical calculations. P < 0.05 was
considered significant.
Results
Construction of a novel bispecific antibody platform
We sought to design and construct a combination plat-
form that merges advantages of BsAb technology with
that of gene-engineered T-cell therapy. Based upon its
limited endogenous expression by human T-cells, folateFigure 1 Generation of primary human T cells expressing costimulate
antibody. A. Upper left Schematic representing the costimulated ligand; Bs
based BsAB-Immune Receptor gene constructs containing extracellular por
(BsAb-IR-z) or in combination with the CD28 co-stimulatory module (BsAb-
detected by Mov18/ZEL antibody (Enzo Life Sciences) followed by anti-m
Staining was performed 5 days following transduction with lentivirus and com
histograms). Percent transduction is indicated.receptor alpha (FR) was selected for use in immunore-
ceptor construction. We constructed a folate binding
immunoreceptor construct comprised of the extracellu-
lar portion of FR (1-231aa) linked to a CD8α hinge and
transmembrane region, followed by a CD3z signaling
moiety alone (BsAb-IR-z; Figure 1A Schematic). In order
to incorporate simultaneous CD28-mediated signaling
and evaluate whether a functional secondary signal po-
tentiates T-cell activity, a second-generation BsAB-IR
that includes a chimeric fusion of CD28 and CD3-z
intracellular domains was constructed (BsAb-IR-28z).
GFP transduced, or non-transduced T-cells were used as
a specificity control in all experiments. BsAb-IR-z and
BsAb-IR-28z immunoreceptor sequences were trans-
duced into freshly isolated human primary T-cells utilizing
lentiviral vectors. Five days following lentiviral transduc-
tion, BsAb-IR cell surface expression of was measured via
detection of surface FR expression by flow cytometric ana-
lysis utilizing an anti-FRa antibody (MOV18) with a FITC-
labeled anti-mouse secondary antibody. As shown in
Figure 1B, transduction efficiencies were >80% for all
constructs. For all functional assays, transduced T-cells
were equilibrated to 70% by adding untransduced T-cells.
In all T-cell cultures the ratio of CD4 and CD8 T cells was
approximately 30% CD4 and 70% CD8 (data not shown).d ligand for redirectionagainst tumor antigens via bispecific
Ab-IR. Upper right Schematic representation of Folate Receptor alpha
tion of FRa (231aa) fused to the human CD3z cytosolic domain alone
IRFBIR-28z). B. BsAb-IR transgene expression (open histograms) was
ouse FITC or and via GFP expression for control, GFP transduced T-cells.
pared to untransduced T cells, or isotype stained T cells (grey filled
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The BsAb-IR engagers, referred to as frBsAbs, were pro-
duced by chemical heteroconjugation of two mAbs
(Additional file 1: Figure S1), one that binds the extracellu-
lar FR portion of the BsAb-IR (MOV18Ab) on engineered
T-cells and another that targets a chosen tumor-associated
antigen (TAA) (Figure 2A). mAb against CD20 molecule
(rituximab) was used for tumor targeting. Antibody recog-
nizing HER2 (trastuzumab) and an isotype IgG1 were used
as specificity controls in the construction of frBsAbs.
Figure 2B shows Western Blot analysis of the cross-
linked mAbs, following overnight heteroconjugation at
4°C. The products of the heteroconjugation were re-
solved by SDS-PAGE (4–15% gradient) and stained
with Gelcode Blue (Pierce). By densitometric quantita-
tion using Gel Doc analysis and Quantity One software
(Bio-Rad), the mixture consisted of 21% of the desired conju-
gated heterodimers, 64% unconjugated monomers and 25%
multimers for the CD20-frBsAb preparation. The HER2frB-
sAb mixture consisted of 11% conjugated heterodimers, 76%Figure 2 A. Schematic illustration of the functional activity of primary h
binding immune receptor (BsAb-IR) when redirected against tumor cell
tumor associated antigen (TAA) on tumor cell surface, facilitates crosslinkin
activation. Unlike traditional bispecific antibody (BsAbs) platforms that i
costimulatory signaling capacity, incorporation of CD28 co-stimulation i
redirected human T-cells, in comparison to a first generation BsAb-z-IR lackin
of BsAb-IR in preselected human T cells ex vivo allows for a selective activation
B. SDS-PAGE (4-15% gel) analysis of chemically heteroconjugated anti-C
alpha) with anti-Her2/neu (Herceptin, Genentech, San Francisco, CA) or anti-C
electrophoresis shows anti-BsAb-IR monoclonal antibody, MOV18 (lane 2); ant
containing monomers, dimers, and multimers (lane 3, 5 and 7 and 8). C. Grap
mixture for each antibody format following chemical conjugation.monomers and 13% multimers, and the IgGfrBsAb control
mixture was 31%, 58%, and 9%, respectively as represented
on the graph (Figure 2C). Previous preclinical and clinical
studies have shown no significant difference in binding and
specificity between the purified and unpurified heteroconju-
gates [29]. Therefore, the unpurified heteroconjugated
material was used for arming of the BsAb-IR engi-
neered T-cells.
Primary human T-cells expressing BsAb-IR are specifically
activated by immobilized anti-BsAb-IR antibody
To determine whether crosslinking of BsAB-IRs on the
T-cell surface results in a specific immune-activation of
engineered T-cells, BsAb-IR T-cells were cultured in
plates coated with immobilized anti-BsAb-IR antibody
(MOV18 Ab), control IgG1 or rituximab, or left un-
coated. BsAb-IR-z expressing T-cells exclusively pro-
duced pro-inflammatory cytokine interferon-g (IFNg) in
response to anti-BsAb-IR antibody (MOV18 Ab) stimula-
tion, but not to control antibodies; anti-CD20 (rutixumab)uman T-cells engineered to express a chimeric bispecific antibody
s with a unique bispecific antibody (frBsAbs). The frBsAb, bound to
g with BsAb-IRs on the T-cell surface and promotes BsAb-IR T-cell
ndiscriminately engage all T-cells via the CD3 molecule and lack
n a second generation BsAb-28z-IR augments antitumor activity of
g an engineered costimulatory domain. In addition, engineered expression
of the chosen T-cell population, not the open repertoire of all T cells.
D3 [OKT3 (immunoglobulin (Ig)G2a); Orthobiotech], or MOV18 (anti-FR
D20 (Rituxan, Genentech) and control IgG. The SDS-polyacrylamide gel
i-CD20 monoclonal antibody, (lane 4); and the heteroconjugated product
h showing the percentage of heterodimerized bispecific antibody in the
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did not show any significant immune-reactivity. Single cell
analysis by intracellular cytokine production confirmed
that IFNg production was restricted to T cells expressing
BsAb-IR-z; T cells lacking BsAb-IR did not (Figure 3B).
Since the BsAb-IR comprise extracellular portion FRa
which binds folic acid with high affinity, we tested whether
high levels of folic acid can mediate BsAb-IR T-cell activa-
tion. As shown by intracellular cytokine analysis, BsAb-IR
T-cells did not produce IFNg in the presence of supra-
physiological levels of folic acid.
Costimulatory properties of BsAb-binding immune
receptor (BsAb-IR)
Production of multiple proinflammatory cytokines can
improve cytolytic function and contribute to in vivo ac-
tivity [32]. Costimulation promotes T-cell activation,
proliferation and effector function and therefore repre-
sents a key aspect in potentiating T-cell responses in
cancer immunotherapy. The costimulatory properties ofFigure 3 Activation of BsAb-IR expressing T-cells depends on the spe
production by BsAb-IR-z and untransduced T-cells stimulated with immobi
IgG1. Overnight culture supernatants were analyzed for human IFNg cytoki
pg/ml from triplicate wells. B. Intracellular IFNg staining of BsAb-IR-z and
immobilized anti-BsAb-IR (MOV18) or IgG1 antibody, or cultured in a groBsAB-IR were therefore evaluated in an experimental
setting where the first signal required for T-cell activa-
tion and the second costimulatory signal are triggered
by the engagement of BsAb-IR-28z by frBsAb. CD28 is
one of the best-characterized costimulatory molecules
expressed by T-cells, providing signals critical for opti-
mal T-cell activation, cytokine production, proliferation,
and survival [33]. Having incorporated the CD28 endo-
domain into the BsAB-IR, we evaluated the contribution
of CD28 costimulatory signals in BsAB-induced activation
of human T-cells. We first tested whether cross-linking of
the costimulated BsAb-IR-28z receptor induces more po-
tent T-cell activity in comparison to activation triggered
by the first generation BsAb-IR-z immunoreceptor, which
lacks a costimulatory signaling domain. BsAb-IR-28z,
BsAb-IR-z or untransduced T-cells were added to wells
containing immobilized anti-FR antibody (MOV18) or
IgG isotype antibody, and incubated for 16 hours before
culture supernatants were collected and measured for type
and amount of proinflammatory cytokines secreted incific engagement and crosslinking of immunoreceptors. A. IFNg
lized anti-BsAB-IR antibody (MOV18), anti-CD20 rutixumab, or mouse
ne by ELISA. Concentration of IFNg is expressed as mean ± SEM in
untransduced T-cells following 6 hr stimulation with 0.1ug of an
wth media supplemented with folic acid (40 mg/l) for 12 hr.
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IR-z T-cells both secreted IFNg, interleukin-2 (IL-2) and
tumor necrosis factor-alpha (TNFa) cytokines when stim-
ulated with anti-FR, but not control, antibody (Figure 4).
Little to no IL-4 or IL-10 cytokines was detected suggest-
ing a preferential Th1-cytokine response. GFP transduced
control T-cells did not secrete cytokine under either anti-
body condition. More notably, primary human T-cells ex-
pressing a BsAb-IR containing the CD28 endodomain
secreted higher levels of proinflammatory cytokines com-
pared to T-cells with the BsAb-IR-z alone (n = 4). Similar
increases in the levels of secreted IFNg, IL-2 and TNFa cy-
tokines occurred in the BsAb-IR-28z group. In all cases,
cytokine secretion by BsAb-IR T-cells was specific, and
dependent on the engagement of the BsAb-IR, demon-
strated by little constitutive cytokine production in the ab-
sence of immobilized anti-FR antibody, or in the presence
of the isotope control antibody. Importantly, stimulation
of BsAbIR-T cells with immobilized antibodies including:
trastuzumab, rituximab and/or IgG1 did not induce secre-
tion of proinflamatory cytokines (data not shown).
Evaluating BsAb-directed antitumor responses of
BsAb-IR+ T-cells in vitro
Finally, we investigated the cytotoxic potential of BsAb-
IR T-cells. To evaluate whether BsAb-IR-mediated acti-
vation of T-cells by cancer cell bound frBsAb facilitates
specific target cell killing, BsAb-IRs T cells were assayed
for their capacity to specific lyse Ramos, Daudi and
AE17 cell lines. We first evaluated the potency of the
combination of a CD20frBsAb and BsAb-IR T-cells. Cell
surface expression of CD20 on lymphoma cell targetsFigure 4 The amount of cytokines produced by BsAb-IR+ T-cells is de
within the immune receptor construct. Comparison of cytokine product
supernatant from triplicate co-cultures were measured for proinflammatory
IL-10 cytokine concentrations (pg/ml) were measured from cultures of BsA
0.1ug of an immobilized anti-BsAb-IR (MOV18) antibody. Representative dawas confirmed by flow cytometry. Human Burkitt’s
lymphoma cell lines, Ramos and Daudi, expressed high
levels of CD20, with a specific mean fluorescence inten-
sity (MFI) of 2189 and 2602 respectively (Figure 5A).
The mouse mesothelioma cell line, AE17 did not express
CD20 antigen on cell surface and was used as an antigen
specificity control. Target cells were exposed to frBsAb
bearing either an anti-CD20 (CD20frBsAb), irrelevant
anti-HER2 (HER2frBsAb) or control IgG (IgGfrBsAb)
antibody arm at 100 ng per 106 cells for 30 minutes, la-
beled with 51Cr, and washed before culture with T-cells.
Cytotoxicity was measured at indicated E:T ratios of 1,
3, 10 and 30 to 1 in standard 4-hour 51Cr-release assays.
BsAb-IR T-cells exhibited specific redirected cytotoxic
activity against CD20+ lymphoma cells when using CD20-
frBsAbs at E:T ratios >10:1. Cytotoxic activity was not de-
tected in co-cultures where anti-HER2 or IgG control
frBsAbs were used for redirection (Figure 5B). After
4 hours, BsAb-IR transduced T-cells specifically lysed
CD20frBsAbs targeted Ramos (20% ± 3%, 30:1) and Daudi
(30% ± 4%, 30:1) cell targets (P < 0.05), but not when redir-
ected with control HER2 or IgG1frBsAbs (5% ± 1.5% and
4.6% ± 2%, respectively at 30:1; n = 3). CD20frBsAb redir-
ected cytotoxicity of the CD20-negative AE17 cell line was
not observed at any E:T ratio (Additional file 2: Figure S2).
In parallel studies, BsAb-IR-28z T-cells, but not con-
trol GFP T-cells, produced high levels of IFN-g in co-
culture with Ramos cells but only when redirected with
a CD20frBsAb (Figure 6A). Redirection with other
frBsAbs had no impact on cytokine secretion. Culture
supernatants were pooled and measured for various
T-cell produced cytokines by cytokine bead arraypendent on the presence of the CD28 costimulatory domains
ion by T-cells transduced with different BsAb-IR constructs. Pooled
cytokine secretion by cytokine bead assay. IFNg, IL-2, TNFa, IL-4 and
b-IR-z, BsAb-IR-28z and control GFP transduced T-cells stimulated with
ta from 4 independent assays are shown.
Figure 5 frBsAb-mediated activation of T cells by antigen-bound bispecific antibody (frBsAb) facilitates specific target cell killing. A.
The CD20 cell surface expression (open histograms) on cancer cell lines was detected with biotinylated anti-CD20 mAb rituximab and evaluated
by flow cytometry. Numbers represent mean fluorescence intensity (MFI). B. Antigen-specific tumor killing by CD20frBsAb redirected BsAb-IR
T-cells. Primary human T-cells transduced to express BsAb-IR-28z or GFP (control) were co-cultured with Cr51-labeled Ramos, and Daudi
tumor cells, pretargeted with indicated frBsAb for 4 hrs at the indicated effector to target ratio. Percent specific target cell lysis was calculated as
(experimental - spontaneous release) ÷ (maximal - spontaneous release) × 100. Data represent the means ± SD for 3 different experiments. * P = 0.0082
for BsAb-IR-28z T-cells/CD20frBsAB versus IgGfrBsAb redirected BsAb-IRs against Ramos cells. ** P = 0.0166 for BsAb-IR-28z T-cells/CD20frBsAB versus
IgGfrBsAb redirected BsAb-IRs against Daudi cells.
Figure 6 Anti-tumor activity of BsAb-IR-28z engineered T-cells. A. BsAb-IR-28z + T lymphocytes produce inflammatory cytokines when
redirected with antigen-bound frBsAbs. CD20 redirected BsAb-IR, but not GFP (control) T-cells produce high levels of IFNg against CD20-positive
Ramos tumor cells. BsAb-IR-28z or GFP transduced T-cells were cultured overnight with an equal number of CD20frBsAb, or control frBsAbs pretargeted
CD20-positive Ramos cancer cells. Overnight culture supernatants were analyzed for human IFNg cytokine by ELISA. Concentration of IFNg is expressed
as mean ± SEM in pg/ml from triplicate wells. B. Cytokine bead-array analysis of cytokine production (pg/ml) by BsAb-IR-28z + T-cells or GFP+ T-cells.
Supernatants from three independent cultures were harvested 16 h post-stimulation, pooled and assessed for measurable cytokine.
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kines were all detected in supernatants from the co-
culture of BsAb-IR-28z T-cells, but not GFP T-cells,
and Ramos cells exposed to CD20frBsAb (Figure 6B).
IL-4 and IL-10 secretion were not detected. Again, no
substantial cytokine production by BsAb-IR-28z T-cells
or GFP T-cells was observed in the presence of antigen
specificity control frBsAbs.
Discussion
Tumor cells express various proteins on their surfaces
that differentiate them from healthy tissues, either by
levels of expression or by revealing novel antigens. Mul-
tiple antibodies against tumor associated antigens (TAAs)
have been identified and exploited against different types
of cancers though their mode of activity is largely inde-
pendent of T-cell involvement. In order to enlist and
mobilize of T-cells against cancer and maximize antibody
targeted therapy, innovative methods have been designed
to allow T-cells to be redirected against TAAs via TAA-
specific antibodies. In one approach, relying on genetic
retargeting of cytotoxic T-cells with antibody [34,35], a
chimeric gene constructed that encodes an extracellular
antibody specific for a TAA in the form of a single-chain
variable fragment (scFv) in tandem with a gene sequence
that encodes intracellular T-cell signaling domains, such
as those from the CD3zeta subunit of the T cell receptor
complex for T-cell activation and from costimulatory mol-
ecules to support T-cell effector function, proliferation
and survival. The gene encoding this chimeric antigen re-
ceptor (CAR) is then introduced into T-cells for adoptive
T-cell therapy [36]. Transfer of autologous T-cells engineered
to express CARs with costimulatory domains has shown re-
markable anti-tumor activity in CD19+ hematological malig-
nancies [37,38]. Another strategy to target T-cells to epitopes
recognized by antibodies is to develop dual specificity
antibody-like molecules that possess antigen-binding specifi-
city for both a protein expressed on the target tumor cell
and a protein expressed by effector T-cells, resulting in their
coupling. Commonly, those molecules, known as a Bispecific
Antibodies (BsAbs), recruit and activate T-cells through
binding a CD3 subunit of the T cell receptor complex for
redirected lysis of tumor cells. This approach has been used
to redirect T-cells toward a variety of TAAs, including
CD19, Her2, and CD20 targets. Perhaps the most advanced
BsAb is Blinatumomab [39], an investigational Bispecific T
cell engager (BiTE®) antibody construct designed to direct
T-cells against target cells expressing CD19 expressing
B-cell derived leukemias and lymphomas, which has
received orphan drug designation from the FDA for a
wide array of CD19 expressing hematological malig-
nancies. While BsAbs have shown promising results in
liquid tumors and in preclinical studies of solid tu-
mors, their clinical activity has been limited in solidmalignancy but may be enhanced with more robust ac-
tivation of effector T-cells.
Here, we sought to establish proof of concept for a
unique approach that combines the advantages of BsAb
therapies and gene-modified T-cell therapy. To address
the issue of insufficient lymphocyte activation mediated
by BsAbs, we designed, constructed and functionally char-
acterized genetically-modified human T-cells expressing a
unique co-stimulated immunoreceptor for bispecific anti-
body engagement, referred to as a BsAb-IR. Analogous to
conventional BsAbs, our novel platform allows for the re-
direction of both CD8+ and CD4+ T-cells expressing a
BsAb-IR against tumor targets via interaction with unique
frBsAb intermediate, however, incorporation of a costimu-
latory signaling domain within the BsAb-IR construct re-
sults in heightened T-cell function. frBsAb-mediated
activation of costimulated BsAb-IR-28z T-cells elicited
enhanced production of multiple Th1-type proinflam-
matory cytokines, including IFN-g, TNF-a and IL-2, in
comparison to activated BsAb-IR-z T-cells that lack a
costimulatory signaling endodomain. These results are
consistent with the notion that BsAb-IR T-cell have
the capacity to receive simultaneous TCR and costimula-
tory signals via crosslinking of BsAb-IRs on the T-cell sur-
face upon frBsAb engagement. In addition to cytokine
secretion, antigen-specific target cell lysis occurs when
BsAb-IR T-cells are redirected by TAA-specific frBsAb
against TAA-expressing tumor cells. To the best of our
knowledge, this strategy of utilizing primary human T-cells
engineered to express a co-stimulated immune receptor
for BsAb-mediated anti-tumor activity has not been previ-
ously reported. Although the specific tumor lysis mediated
by this first generation of redirected BsAb-IR T-cells was
less robust than previously reported for T-cells redirected
with conventional BsAb [30,40], this platform is highly tun-
able for optimization. One likely explanation for this mod-
est lytic activity is the low concentration of functionalized
frBsAb heterodimer used in these assays, which was less
than 20% of total antibodies mixture following heterocon-
jugation. Accordingly, selective isolation of functional het-
erodimers from the antibody mixture may significantly
improve in vitro lytic activity of BsAb-IR T-cells.
Activation of T-cells is triggered by signals transmitted
through the T-cell receptor/signal transduction complex
(TCR/CD3 signal 1). Other costimulatory receptor-ligand
interactions between T-cells are needed, however, for
comprehensive T-cell stimulation (signal 2). One of the
best-characterized costimulatory molecules is CD28,
which plays a complex role in regulating T-cell func-
tion after interaction with its ligands, B7-1 (CD80) and
B7-2 (CD86) [41,42]. Costimulation through CD28 and
TCR/CD3 complex leads to high-level production of
IL-2 and regulates T-cell proliferation [33]. Moreover,
CD28 costimulation is thought to be required not only
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tosis mediated by the CD95 (APO-1/Fas) death recep-
tor [43]. As reported, the lack or loss of CD28 ligands
expression by tumors may, therefore, lead to insuffi-
cient T cell activation [44,45], where continued signal-
ing through the T-cell receptor alone (CD3) can lead
to anergy or antigen induced cell death (AICD) [46,47].
Thus, T-cells redirected and activated by a conventional
CD3-signaling BsAb bound to the cancer cell surface are
unlikely to obtain necessary secondary costimulatory sig-
nals, and may result in inefficient BsAb-mediated T cell
activation and antitumor activity in patients. In previous
studies, co-administering anti-CD28 antibodies or B7-scFv
fusion proteins was shown to deliver a costimulatory sig-
nals [48,49]. However, this kind of systemic activation of
the costimulatory ligand was accompanied by unexpected
systemic toxicities in vivo, as observed after superagonistic
anti-CD28 mAb TGN1412 application [50,51]. For this
reason, and in order to localize the immunologic response
to the tumor, others have attempted to transfer costimula-
tory ligands into the tumor cells. Indeed, 4-1BBL expres-
sion by tumor cells inhibited tumor outgrowth and
induced strong cytotoxic T-cell response followed by
long-term immunity in diverse mouse models [52]. How-
ever, the clinical applicability of such a strategy is chal-
lenged by the need for selective, efficient and safe gene
transfer into the tumor cells. Thus, the generation of a
novel, costimulated and specific receptor composed of a
short binding moiety linked to T-cell signaling domains,
CD3z and CD28, and construction of a novel bispecific
antibody against a TAA and the extracellular domain of
the costimulatory immune-receptor, may circumvent some
of the potential major limitations associated with infusing
co-stimulatory ligands together with BsAbs, specifically by
permitting simultaneous activation and costimulation of a
pre-selected T cell population in localized antigen-rich en-
vironment, As a proof of concept, we chose the extracellu-
lar portion of folate receptor alpha (FRa) as a BsAB
partner. FRa is a 38 kDa glycosylphosphatidylinisotol
(GPI)-anchored protein that binds folic acid with high
affinity and transports folate by receptor-mediated endo-
cytosis [53]. FRa exhibits limited normal tissue distribu-
tion, with measurable expression restricted largely to the
apical surfaces of a few epithelia, predominantly in the
kidney cortex, lung and choroid plexus [54]. Restricted
distribution, and importantly, the lack of FRa expression
on T-cells, makes this antigen a good candidate for a cre-
ation of a unique T-cell surface CD28 costimulated
engager for bispecific antibody, the frBsAb-IR, yet other
binding partners are under investigation.
In these principle-establishing studies, we generated bispe-
cific antibodies by chemical conjugation (Additional file 1:
Figure S1) and demonstrated that these hybrid molecules
can redirect specific cytotoxicity of BsAb-IR engineeredT-cells toward tumor cells expressing CD20 in vitro.
These BsAbs were comprised of clinical-grade bivalent
antibodies with low heterodimerism. While bivalency may
increase IR crosslinking, limited heterodimers may reduce
overall potency. To address this, future studies that in-
corporate newer BsAb formats, such as BiTE (bi-specific
T cell engager) [55] and DART (dual affinity retargeting)
[56], which have proven to be more potent than chem-
ically conjugated BsAbs, are warranted.
In line with the known role of costimulatory signals in
T-cell function [33], we found that BsAb-IR-28z T-cells
produced at least three Th1 type cytokines, IFN-g, IL-2
and TNF-a, as well as MIP-1a, at levels that were signifi-
cantly higher than those produced by BsAb-IR-z T-cells,
following the engagement by frBsAb. This is of special
importance, since the release of multiple cytokines and
chemokines may recruit and activate endogenous im-
mune cells to enhance the local antitumor response.
Taken together, our in vitro data illustrate the high po-
tential of a costimulated BsAb-IR approach, and supports
its further optimization and evaluation in preclinical
models. Our in vitro findings are in line with previously
published data showing an enhanced BsAb-mediated anti-
tumor response by provision of a CD137 signal in trans
using a second recombinant Ab directed against a non-
tumor specific cellular target [57]. In contrast to this
approach, BsAb-IR has the unique advantage to simul-
taneously and locally activates selected population of
gene engineered T-cells, and trigger the co-stimulatory
signals upon cross-linkage of the BsAb-IRs to its target
cell by application of one single bispecific molecule.
Conclusions
In conclusion, a strategy of using genetically modified
primary human T-cells expressing a co-stimulated im-
mune receptor and armed with bispecific molecules offers
the possibility of a straightforward method for delivery
of co-stimulatory signals to antigen-redirected cyto-
toxic T-cells. This approach extends upon our experience
in bridging tumor cells with T-cells using biotinylated anti-
bodies that engage an avidin-based immunoreceptor on
the engineered T-cell surface [58], however, by comparison,
the BsAb-IR described here is fully human in composition
reducing the risk for transgene immunogenicity, and
can be bound with antibodies with affinities higher than
that obtainable using dimeric avidin binding to biotin
(KD = 0.5 +/− 0.1 nM). BsAb-IR T-cells encountering
antigen-bound frBsAbs undergo potent activation that is
enhanced by coordinate costimulatory signaling stemming
from the BsAb-IR itself. Since CD28 costimulatory signals
may not only bolster augmented T-cell function but also
prevent T-cell AICD, we believe that the principles estab-
lished in this study will significantly enhance anti-tumor
activity of targeted BsAb-based tumor immunotherapy.
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Additional file 1: Figure S1. Schematic illustration of the construction
of anti-BsAb-IR × TAA bispecific antibody (frBsAb). Anti-BsAb-IR (MOV18
Ab) is cross-linked with Traut’s reagent and anti-TAA is cross-linked with
SulfoSMCC [sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate;
before heteroconjugation overnight under the conditions described.
Additional file 2: Figure S2. Tumor killing by redirected BsAb-IR T-cells is
antigen-specific. CD20frBsAb redirected cytotoxicity of the CD20-negative
AE17 cell line by BsAb-IR T-cells was not observed. Primary human T-cells
transduced to express BsAb-IR-28z or GFP (control) were co-cultured
with Cr51-labeled CD20-negative AE17, mouse mesothelioma cell line,
pretargeted with indicated frBsAb for 4 hrs at the indicated effector to
target ratio. Percent specific target cell lysis was calculated as
(experimental - spontaneous release) ÷ (maximal - spontaneous release) × 100.
Data represent the means ± SD for 3 different experiments.
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